PIK3CA and prostate cancer: It has been recently shown that concomitant BRCA1/2 downregulation following PI3K inhibition in breast cancer and prostate cancer is sufficient for the induction of HR deficiency, rendering cancer cells to acquire sensitivity to PARP inhibition [19, 23].